Objectives: Norfloxacin is a synthetic broad-spectrum antibacterial drug having poor bioavailability and pH-dependent solubility. The purpose of present study was to develop gastroretentive floating multiparticulate drug delivery system of Norfloxacin.
Conclusion:
The significant outcome obtained with the study indicates that such an approach can be effectively employed for improvement of bioavailability of drugs having poor absorption in lower part of the gastrointestinal tract with enhanced therapeutic efficacy.
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INTRODUCTION:
Oral route plays an important role in therapy as it is the most preferable and convenient route of drug delivery system. 1 Gastroretentive drug delivery systems (GRDDs) are one of the advanced approaches for the novel drug-delivery systems in which drug is retained in the stomach for a prolonged period of time. 2, 3 GRDDSs are particularly suitable for drugs having a narrow absorption window, drugs that act locally in a part of the gastrointestinal tract (GIT), drugs which are unstable in intestinal fluids and drugs that exhibit poor solubility in the intestinal tract. 4 Floating drug delivery system (FDDs) is one of the most prominent approaches of GRDDs, characterized by the capacity of the formulation to float in and over the gastric contents. FDDs are low density system which allows them to remain buoyant in the stomach for a prolonged period of time. In the development of FDDs based on the mechanism of buoyancy widely employed technology is effervescent systems. In the effervescent systems, carbon dioxide gas production occurs due to the reaction of carbonates and bicarbonates present in the formulation with gastric fluid. The gas that forms is entrapped in the polymers, which allows the system to remain buoyant.
u n c o r r e c t e d p r o o f
The FDDs are effectively used to design sustained drug delivery system and improvement in overall oral bioavailability of drugs. [5] [6] [7] Norfloxacin is fluoroquinolone anti-infective antibacterial drug firstly used in the treatment of urinary tract infections, prostatitis, gonorrhoea and genital tract infections.
8
It has 30-40% bioavailability with plasma half-life of 3 to 4 hours thus required multiple dosing to maintain adequate plasma concentration in the treatment.
9
Norfloxacin is also poorly absorbed from the lower part of the gastrointestinal tract and it is well absorbed from the stomach. The solubility of norfloxacin in water is pH-dependent which increases sharply with decreasing pH below 5.
10,11
The therapeutic dose of Norfloxacin is very high (400 mg orally twice daily) in the treatment of urinary tract infections.
12
Many novel approaches have been reported which are used for bioavailability enhancement of norfloxacin, either directed towards development of single unit system or unable to produce significant effect on improvement of bioavailability. Thus it was decided to develop a floating multiparticulate drug delivery system of Norfloxacin that could produce sustained release so as to maintain drug plasma levels for improving bioavailability and therapeutic effects.
The floating multiparticulate has been developed in which Norfloxacin pellets containing different ratios of sodium bicarbonate (NaHCO3): Hydroxylpropyl Methyl Cellulose (HPMC) K15M was prepared by extrusion spheronization process. The pellets are coated with Eudragit RL100 on fluidized bed processor by using bottom spray technique. The amount of the effervescent agent and coating level of Eudragit RL100 polymeric membrane were evaluated and optimized in terms of floating ability and drug release properties.
MATERIALS AND METHODS

Materials:
Norfloxacin was a kind gift provided from Aarti drugs ltd, Mumbai, India. Eudragit RL100 was provided by Evonik, Mumbai, India. As received all the other chemicals were used are of analytical reagent grade. The Norfloxacin core pellets were prepared using wet granulation method by extrusion and spheronization technique. Powder mixture of Norfloxacin, microcrystalline cellulose, was mixed in mortar for 20min.This was followed by addition of binding liquid consisting of 3% polyvinylpyrrolidone K30 in water. The obtained wet mass was passed through BSS sieve no.16 to get the extrudates. The prepared extrudates were then transferred to spheronizer (Shakti Pharmatech, Ahmedabad, India) and spheronized at different spheronizing speed to get pellets.
The prepared core pellets were oven dried overnight at 60 ○ C.
Experimental Design:
A 3-level, 3-factor, 17 run experimental box-behnken design was adopted to optimize levels of variables in the pellets formulations. The selected independent variables were amount of MCC i.e. microcrystalline cellulose (X1), PVP (K30) i.e. polyvinylpyrollidone (X2), and spheronizing speed (X3) as shown in (Table 1 ). The dependent variables were aspect ratio (Y1) so as to predict the sphericity and hardness (Y2).The generation of experimental runs, ANOVA study and optimization were carried out by Designexpert® software 10.
The optimized norfloxacin pellet batch in terms of sphericity and hardness was selected followed by incorporation of NaHCO3 and HPMC K15M in the ratio of 1:1, 1:2 and 2:1 (w/w) on a dry solid basis as indicated in (Table 2b ).
Coating of Norfloxacin pellets containing NaHCO3: HPMC K15M
The Norfloxacin pellets containing NaHCO3: HPMC K15M in the ratio of 1:1 was further coated with EudragitRL100 using fluidized bed processor (ACG, Miniquest-F, Mumbai, India), to obtain weight gain of 5%, 10% and 15% w/w as shown in (Table 2 10mg of Norfloxacin accurately weighed and was dissolved in 100 ml 0.1 N HCl in volumetric flask to get 100μg/ml stock solution. This solution was further diluted with 0.1 N HCl to get solutions in concentration range of 1 to 10μg/ml. Absorbance of these solutions were determined spectrophotometrically (Shimadzu 1700, Japan) at 273 nm.
13,14
Fourier Transform Infra-Red (FTIR) spectrum:
The powder sample of Norfloxacin, Eudragit RL100 and physical mixture of Norfloxacin and polymer (Eudragit RL100) was kept in dryer to make moisture free.
The dry sample of powders was separately mixed and triturated with dry potassium bromide. This mixture was placed in DRS assembly sample holder. The infrared spectrum was recorded and the spectral analysis was done (Shimadzu,8400S, Japan). Norfloxacin pellets equivalent to 400 mg were grounded using mortar pestle and transferred into 50ml volumetric flask containing 0.1 N HCL and volume was made to 50 ml. The mixture was sonicated for 10 minute to ensure complete extraction of drug. The solution was filtered through whattmann filter paper and assayed spectrophotometrically (Shimadzu 1700, Japan) at 273nm to determine the percent drug content.
16, 17
In vitro drug release studies:
Drug release studies of Norfloxacin pellets were performed by USP Dissolution
Apparatus-I (Veego DA-8D, India). The dissolution studies were carried out with 900 ml 0.1N HCl as dissolution medium at 37±0.5ºC on 50 rpm. Pellets equivalent to 400 mg of Norfloxacin were weighed and transferred to the dissolution apparatus. 10 ml aliquot was withdrawn and immediately replaced by the same volume of fresh medium to maintain sink condition. The aliquot was filtered through whattman filter paper and absorbance was measured at 273nm using UV spectrophotometer (Shimadzu 1700, Japan) to determine the drug release.
16-18
In vitro buoyancy studies.
19-21
The time required for the pellets to rise to the surface and float as floating lag time and total duration of time by which pellets remain buoyant i.e. total floating time was determined. The floating pellets (100) was kept in USP Type -I dissolution apparatus, the dissolution medium used was 0.1N HCl conditions were 37ºC ± 5ºC at 50 rpm.The percentage of floating was determined by following equation:
Floating pellets (%) = ×100
Scanning electron microscopy (SEM):
The surface morphology of optimized coated pellets was examined using the scanning electron microscope. SEM analysis was performed using Carl Zeiss Supra 5, Germany Scanning Electron Microscope. The pellets samples were mounted directly onto aluminium stages and were sputter coated with gold /Palladium mixture for 1 min under an argon atmosphere. The coated pellets were mounted onto stubs using double-sided adhesive tape. The size distribution of the gastroretentive pellets was determined using mechanical sieve shaker (Make-Kumar) A series of BSS standard stainless steel sieves no 8, 10, 22, 36, 44, 60, and 100 were arranged in order of decreasing aperture size.
Accurately weighed amount of drug loaded gastroretentive pellets from each batch were placed on the upper most sieve. The sieves were shaken for a period of 10 minutes and the material retained on each sieve was weighed separately. Graph of mean size vs. % weight retained was plotted to analyse pellet size distribution.
23, 24
Physical characterization:
The micromeritics properties (bulk density, tapped density, Carr's index, Hausner's ratio and angle of repose), of the floating pellets were determined. Friability of the pellets was determined by using USP friability test apparatus. Friability of the pellet formulations was determined as the percentage of weight loss after 200 revolutions of 6.5 g of the core pellets in a friabilator (Roche Friability Tester, India). The hardness of the pellets was determined using digital hardness tester (Veego, India).
25-27
Pellets sphericity:
Pelletssphericity was determined by measuring the feret diameter and perpendicular diameterof pellets by vernier calliper. From that aspect ratio (AR) is calculated i.e.
(ratio of longest feret diameter and its longest perpendicular diameter). 
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RESULT AND DISCUSSION
UV
Fourier Transform Infra-Red (FTIR) spectrum:
The IR spectrum of Norfloxacin, Eudragit RL100 and physical mixture of Norfloxacin and polymer (Eudragit RL100) was obtained by using FTIR ( Figure   2 ). 
Drug Content:
The drug content in all pellet formulation was determined by UV spectroscopy method and was found to be between 96.75±0.8% to 98.78±0.45% which indicated that the coating on the pellets also gives good reproducibility of drug content.
Optimization of Norfloxacin pellets:
To optimize the Pelletization process MCC, PVP K30, and Spheronizing speed was varied at different levels. 17 batches were prepared using box-behnken design, aspect ratio and hardness of pellets was determined as response as indicated in (Table   3 ). (Table 4 ). In batch B-18 the time requires to release above 80% of drug and total floating time was 4 hours. This type of behaviour could be attributed that once the HPMC gets dissolved there was no polymeric membrane which could entrap the generated CO2gas. Hence, batch B-18 containing NaHCO3and HPMC K15M in the ratio of 1:1was further selected for coating with Eudragit RL 100 to design complete floating drug delivery system pellets. Eudragit RL 100 coating was given in order to increase the total floating time and to sustain the release of norfloxacin. Three batches (B-21, B-22, and B-23) were prepared with Eudragit RL 100 coating with weight gain of 5%, 10% and 15% by weight and evaluated for drug release and floating behaviour. Mean±S.D; n = 3.
Among the three complete floating drug delivery system pellets batches B-21, B-22, and B-23, batch B-22 was found to be optimized based on the criteria of attaining minimum floating lag time (less than 10 minutes), maximum total floating time and maximum value of drug released in 8 hours.
Scanning electron microscopy (SEM):
The Particle size distribution analysis of pellets:
The particle size distribution analysis of pellets indicates narrow size distribution in which most of the pellets are in the size range of 1000µm to 1200 µm as shown in (Figure 7 ). Mean±S.D; n = 3.
CONCLUSION:
The gastroretentive multiparticulate drug delivery system of norfloxacin based on gas generation technique was successfully designed and developed. The identification and purity of drug was affirmed by conducting infrared and UV spectroscopy studies.A 3-level, 3-factor, 17 run experimental box-behnken design was employed to optimize norfloxacin pellets in terms of sphericity and hardness required to attain effective coating subsequently.The pellets batch obtained at spheronizing speed 950 rpm containing 35% MCC with 6% PVP K 30 produces pellets with desired sphericity and hardness. NaHCO3 and HPMC K15M in the ratio of 1:1, 1:2 and 2:1 (w/w) on a dry solid basis was incorporated into Norfloxacin pellets and was further coated with EudragitRL100 using fluidized bed processor to obtain weight gain of 5%, 10% and 
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